Skip to content
Screener

Total Equity at other companies

Merck & Co. logo
Merck & Co.MRK
$41.93B-14.4%
Savara logo
SavaraSVRA
$176.04M+19.1%
Indivior Pharmaceuticals, Inc. logo
Indivior Pharmaceuticals, Inc.INDV
-$144M+49.5%
Theravance Biopharma logo
Theravance BiopharmaTBPH
$290.59M+75.1%
LQD
Liquidia CorporationLQDA
$108.58M+118%
United Therapeutics logo
United TherapeuticsUTHR
$6.4B-10.8%

Other financials

Income statement

See full
Operating income-$14.9M-30.0%
Net income-$13.2M-27.6%
EPS (diluted)-$0.090.0%

Balance sheet

See full
Cash & equivalents$19.4M+0.2%
Total debt$682.0K-28.7%
Total assets$179.6M+67.8%

Cash flow

See full
Operating cash flow-$16.7M-23.8%
CapEx$102.0K
Free cash flow-$16.8M

Valuation

See full
Market cap$2.63B+197%
Enterprise value$2.61B+239%

Returns & leverage

See full
Return on equity-33.6%-9.4pp
Debt / equity0.0×
Current ratio24.8×+9.4×

Where this comes from

Reported directly by Trevi Therapeutics, Inc. in its filing.

Tagged under the XBRL concept us-gaap:StockholdersEquity.

The source filing: Trevi Therapeutics, Inc.’s 10-Q, filed May 5, 2026.

Filed
May 5, 2026, 4:09 PM EDT
Fiscal quarter
Q1 FY2026
Calendar quarter
Q1 2026
Accession
0001193125-26-206390
AssetsMarch 31,2026 / UnauditedDecember 31,2025
Stockholders’ equity:
Preferred stock: $0.001 par value; 5,000,000 shares authorized at March 31, 2026 and December 31, 2025; no shares issued or outstanding at March 31, 2026 and December 31, 2025.
Common stock: $0.001 par value; 200,000,000 shares authorized at March 31, 2026 and December 31, 2025; and 128,411,048 and 128,306,056 shares issued and outstanding at March 31, 2026 and December 31, 2025, respectively.128128
Additional paid-in capital515,185512,772
Accumulated other comprehensive (loss) income(190)148
Accumulated deficit(342,996)(329,804)
Total stockholders’ equity172,127183,244
Total liabilities and stockholders’ equity$179,606$193,439

Item 1. Condensed Consolidated Financial Statements.

FAQ

What is Trevi Therapeutics, Inc.'s total equity?
Trevi Therapeutics, Inc. (TRVI) reported total equity of $172.13M in Q1 2026.
How has Trevi Therapeutics, Inc.'s total equity changed year-over-year?
Trevi Therapeutics, Inc.'s total equity increased by 73.1% year-over-year, from $99.46M to $172.13M.
What is the long-term trend for Trevi Therapeutics, Inc.'s total equity?
Over 5 years (2020 to 2025), Trevi Therapeutics, Inc.'s total equity has grown at a 46.4% compound annual growth rate (CAGR), from $27.28M to $183.24M.
What does total equity mean?
Net assets attributable to shareholders — total assets minus total liabilities. Represents the book value of shareholders' ownership claim.

Ask your AI about Trevi Therapeutics, Inc.'s total equity.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude